Literature DB >> 18567697

Within-subject variability and analytic imprecision of insulinlike growth factor axis and collagen markers: implications for clinical diagnosis and doping tests.

Tuan V Nguyen1, Anne E Nelson, Christopher J Howe, Markus J Seibel, Robert C Baxter, David J Handelsman, Ray Kazlauskas, Ken K Ho.   

Abstract

BACKGROUND: The utility of insulinlike growth factor (IGF) axis and collagen markers for a growth hormone (GH) doping test in sport depends on their stability and reproducibility. We sought to determine short-term within-subject variability of these markers in a large cohort of healthy individuals.
METHODS: We measured IGF-I, IGF binding protein 3 (IGFBP-3), acid labile subunit (ALS), and the collagen markers N-terminal propeptide of type I procollagen (PINP), C-terminal telopeptide of type I collagen (ICTP), and N-terminal propeptide of type III procollagen (PIIINP) in serum samples obtained on multiple occasions (median 3 per participant) over a 2- to 3-week period from 1103 elite athletes (699 men, 404 women) ages 22.2 (5.2) years [mean (SD)]. We estimated between-subject and within-subject variances by mixed-effects ANOVA.
RESULTS: Within-subject variance accounted for 32% to 36% and 4% to 13% of the total variance in IGF markers and collagen markers, respectively. The within-subject CV ranged from 11% to 21% for the IGF axis markers and from 13% to 15% for the collagen markers. The index of individuality for the IGF axis markers was 0.66-0.76, and for the collagen markers, 0.26-0.45. For each marker, individuals with initial extreme measured values tended to regress toward the population mean in subsequent repeated measurements. We developed a Bayesian model to estimate the long-term probable value for each marker.
CONCLUSIONS: These results indicate that in healthy individuals the within-subject variability was greater for IGF-I than for the collagen markers, and that where a single measurement is available, it is possible to estimate the long-term probable value of each of the markers by applying the Bayesian approach. Such an application can increase the reliability and decrease the cost of detecting GH doping.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18567697     DOI: 10.1373/clinchem.2008.105726

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  14 in total

1.  Novel serum protein biomarkers indicative of growth hormone doping in healthy human subjects.

Authors:  Juan Ding; Shigeru Okada; Jens Otto Lunde Jørgensen; John J Kopchick
Journal:  Proteomics       Date:  2011-07-27       Impact factor: 3.984

Review 2.  Diagnosis of growth hormone deficiency in childhood.

Authors:  Takara Stanley
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2012-02       Impact factor: 3.243

Review 3.  IGF-I/IGFBP system: metabolism outline and physical exercise.

Authors:  R Gatti; E F De Palo; G Antonelli; P Spinella
Journal:  J Endocrinol Invest       Date:  2012-06-18       Impact factor: 4.256

4.  N-terminal propeptide of type III procollagen as a biomarker of anabolic response to recombinant human GH and testosterone.

Authors:  Shalender Bhasin; E Jiaxiu He; Miwa Kawakubo; E Todd Schroeder; Kevin Yarasheski; Gregory J Opiteck; Alise Reicin; Fabian Chen; Raymond Lam; Jeffrey A Tsou; Carmen Castaneda-Sceppa; Ellen F Binder; Stanley P Azen; Fred R Sattler
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

Review 5.  Acromegaly pathogenesis and treatment.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2009-11-02       Impact factor: 14.808

6.  Collagen Metabolism Biomarkers and Health Related Quality of Life in Pulmonary Arterial Hypertension.

Authors:  Zeenat Safdar; Emilio Tamez; Adaani Frost; Danielle Guffey; Charles G Minard; Mark L Entman
Journal:  Int J Cardiovasc Res       Date:  2015

Review 7.  The current status of IGF-I assays--a 2009 update.

Authors:  Jan Frystyk; Pamela Freda; David R Clemmons
Journal:  Growth Horm IGF Res       Date:  2009-10-08       Impact factor: 2.372

Review 8.  Perspective: proteomic approach to detect biomarkers of human growth hormone.

Authors:  Juan Ding; Edward O List; Shigeru Okada; John J Kopchick
Journal:  Growth Horm IGF Res       Date:  2009-06-04       Impact factor: 2.372

9.  Reference Values for IGF-I Serum Concentrations: Comparison of Six Immunoassays.

Authors:  Philippe Chanson; Armelle Arnoux; Maria Mavromati; Sylvie Brailly-Tabard; Catherine Massart; Jacques Young; Marie-Liesse Piketty; Jean-Claude Souberbielle
Journal:  J Clin Endocrinol Metab       Date:  2016-05-11       Impact factor: 5.958

Review 10.  Identification of biological markers for better characterization of older subjects with physical frailty and sarcopenia.

Authors:  Bertrand Fougère; Bruno Vellas; Gabor Abellan van Kan; Matteo Cesari
Journal:  Transl Neurosci       Date:  2015-03-17       Impact factor: 1.757

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.